Last updated: November 21, 2023
Sponsor: Tianjin Eye Hospital
Overall Status: Active - Recruiting
Phase
N/A
Condition
Eye Disease
Vision Loss
Treatment
Pentacam, Corvis ST and CASIA2
Clinical Study ID
NCT06152484
KY2023063
All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Best corrected visual acuity (BCVA) ≥ 20/20;
- No other eye diseases except myopia and astigmatism;
- The cornea was transparent, and there was no cloud or pannus;
Exclusion
Exclusion Criteria:
- The presence of ocular diseases other than myopia and keratoconus;
- Ocular trauma;
- Previous ocular surgery; 4 Patients were required to stop wearing soft contact lensesfor at least 2 weeks and rigid contact lenses for at least 4 weeks before examination;
- Pregnant and lactating women;
Study Design
Total Participants: 200
Treatment Group(s): 1
Primary Treatment: Pentacam, Corvis ST and CASIA2
Phase:
Study Start date:
July 01, 2023
Estimated Completion Date:
April 01, 2024
Connect with a study center
Tiajin Eye Hospital
Tianjin, Tianjin
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.